Evidence map›Paper›PMID 34268406›Full record

ArticleAnnals of translational medicine2021

The pharmacodynamic effect of terlipressin versus high-dose octreotide in reducing hepatic venous pressure gradient: a randomized controlled trial.

Bing Li, Jie Chen, Chun-Qing Zhang, Guang-Chuan Wang, Jin-Hua Hu, Jian-Jun Luo, Wen Zhang, Yi-Chao Wei, Xiao-Qing Zeng, Shi-Yao Chen

Registry-linked trialOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02119884 (Hemodynamic Effects of Terlipressin and High Dose Octreotide on Patients With Liver Cirrhosis Related Esophageal Varices), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02119884 phase4completednot on this map

Hemodynamic Effects of Terlipressin and High Dose Octreotide on Patients With Liver Cirrhosis Related Esophageal Varices: A Randomized, Placebo-controlled Multicenter Trial

TypeinterventionalSponsorShanghai Zhongshan HospitalRan2014 to 2016Enrolled88ConditionsGastric and Esophageal VaricesArmsTerlipressin, Octreotide
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. [Chinese guidelines for clinical diagnosis, treatment, and management of cirrhosis (2025)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Guideline
  2. [Advances in the diagnosis and treatment of portal hypertensive gastrointestinal and bile duct disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. [Guidelines on the management of esophagogastric variceal bleeding in cirrhotic portal hypertension].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Bing LiDepartment of Infectious Diseases, Zhongshan Hospital, Fudan University, Shanghai, China.
Jie ChenDepartment of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China.
Chun-Qing ZhangDepartment of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Guang-Chuan WangDepartment of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Jin-Hua HuDepartment of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Jian-Jun LuoDepartment of Interventional Radiotherapy, Zhongshan Hospital Fudan University, Shanghai, China.
Wen ZhangDepartment of Geratology, Zhongshan Hospital Fudan University, Shanghai, China.
Yi-Chao WeiDepartment of Geratology, Zhongshan Hospital Fudan University, Shanghai, China.
Xiao-Qing ZengDepartment of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China.
Shi-Yao ChenDepartment of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China.
Fudan University · CNShandong Provincial Hospital · CNSun Yat-sen University · CNZhongshan Hospital · CNShandong University · CNThe First Affiliated Hospital, Sun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVasoactive drugs can reduce portal venous pressure and control variceal bleeding. However, few studies have explored the hemodynamic effects of terlipressin and high-dose octreotide in such patients. Our purpose was to evaluate the hemodynamic changes and safety of using terlipressin and high-dose octreotide in patients with decompensated liver cirrhosis.

methodsA multi-center randomized controlled trial was conducted. Cirrhotic patients with a history of variceal bleeding were included. Terlipressin or high-dose octreotide was administered during the procedure of measuring hepatic venous pressure gradient (HVPG). Hemodynamic parameters and symptoms were recorded.

resultsA total of 88 patients were included. HVPG was significantly reduced at 10, 20, and 30 min after drug administration in the terlipressin group (16.3±6.4

conclusionsBoth terlipressin and high-dose octreotide were effective and safe for reducing HVPG. The pharmacodynamic effect of terlipressin persisted longer. The terlipressin group had higher response rates in those with alcoholic cirrhosis (trial number: NCT02119884).

Indexed as

liver cirrhosisoctreotidePortal hypertensionterlipressin

Identifiers

PMID34268406
PMCPMC8246168
OpenAlexW3161883603

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.